Morgan Stanley Reiterates Overweight on Omada Health, Maintains $30 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
Morgan Stanley analyst Craig Hettenbach reiterates Omada Health (NASDAQ:OMDA) with a Overweight and maintains $30 price target.
Morgan Stanley analyst Craig Hettenbach reiterates Omada Health (NASDAQ:OMDA) with a Overweight and maintains $30 price target.